6 citations
,
March 2022 in “Frontiers in drug discovery” Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
6 citations
,
March 2018 in “Proceedings - Baylor University. Medical Center” Sarcoidosis can cause severe high calcium levels, hair loss, and kidney failure.
5 citations
,
September 2023 in “Nutrients” Soy protein with isoflavones reduces wrinkles and improves skin hydration in postmenopausal women.
4 citations
,
June 2025 in “MedComm” PROTACs show promise for cancer treatment, but designing them effectively is challenging.
4 citations
,
June 2025 in “Cell Reports” Clonally expanded CD8+ T cells cause alopecia areata.
4 citations
,
May 2025 in “Clinical & Experimental Allergy” Omalizumab is generally safe for chronic urticaria, but hair loss is a common side effect.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
4 citations
,
October 2021 in “Journal of Cellular and Molecular Medicine” White blood cells and their traps can slow down the process of new hair growth after a wound.
3 citations
,
September 2025 in “ChemMedChem” Multitarget drugs are needed to better treat complex diseases.
3 citations
,
September 2024 in “JAAD reviews.” Topical corticosteroids are recommended first for treating pediatric alopecia areata due to their safety and ease of use.
3 citations
,
April 2023 in “Frontiers in Pharmacology” ATP-sensitive K+ channel subunits, particularly Sur2A, play a significant role in various cancers.
3 citations
,
October 2021 in “Clinical, Cosmetic and Investigational Dermatology” Setipiprant did not significantly improve hair growth in men with hair loss.
2 citations
,
August 2024 in “JID Innovations” AD-derived keratinocytes effectively mimic inflammation in atopic dermatitis.
2 citations
,
March 2023 in “Experimental neurology” Pregnenolone might help manage movement issues caused by Parkinson's disease treatment without reducing the medicine's effectiveness.
2 citations
,
October 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” AIRE deficiency causes hair loss similar to alopecia areata in mice.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
1 citations
,
August 2025 in “Journal of Investigative Dermatology” Genetic studies on hair traits can improve understanding of health and disease.
1 citations
,
May 2023 in “European Journal of Human Genetics” Rare ULBP3 gene changes may raise the risk of Alopecia areata, a certain FAS gene deletion could cause a dysfunctional protein in an immune disorder, and having one copy of a specific genetic deletion is okay, but two copies cause sickle cell disease.
1 citations
,
February 2023 in “Applied sciences” The new topical growth hormone formula has high skin penetration and bioavailability.
April 2026 in “Preprints.org” Bioavailable quercetin may help improve aging signs by positively affecting gut health.
January 2026 in “Biology” Androgenetic alopecia is influenced by multiple genes and pathways, with genetic risk varying by population, and personalized treatments are being explored.
December 2025 in “JAAD reviews.” Cross-cultural plant knowledge can improve skin treatments.
November 2025 in “Cosmetics” Autologous Micrografting Technology effectively improves hair growth and is a safe, promising option for hair restoration.
September 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
May 2025 in “Frontiers in Bioinformatics” Jamogenin from plants may help hair growth and is a potential alternative to finasteride.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
Alopecia areata patients show increased inflammation and OX40 activation, suggesting a new treatment target.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.